Read our Annual Report 2018
MorphoSys is dedicated to become a fully integrated biopharmaceutical company. Our business strategy brings more value for patients, investors and partners.
First MorphoSys-antibody approved
Tremfya (Guselkumab) now available in US,Europe and Canada!
We develop exceptional, innovative biopharmaceuticals
to improve the lives of patients suffering
from serious diseases.
Find out more about our therapeutic pipeline.